In last trading session, Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) saw 0.72 million shares changing hands with its beta currently measuring 1.46. Company’s recent per share price level of $13.13 trading at $0.09 or 0.69% at ring of the bell on the day assigns it a market valuation of $1.75B. That closing price of CNTA’s stock is at a discount of -45.39% from its 52-week high price of $19.09 and is indicating a premium of 35.57% from its 52-week low price of $8.46. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.18 million shares which gives us an average trading volume of 958.63K if we extend that period to 3-months.
For Centessa Pharmaceuticals plc ADR (CNTA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 6 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.34 in the current quarter.
Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) trade information
Upright in the green during last session for gaining 0.69%, in the last five days CNTA remained trading in the green while hitting it’s week-highest on Tuesday, 06/24/25 when the stock touched $13.13 price level, adding 7.99% to its value on the day. Centessa Pharmaceuticals plc ADR’s shares saw a change of 47.69% in year-to-date performance and have moved 5.63% in past 5-day. Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) showed a performance of 1.39% in past 30-days. Number of shares sold short was 4.47 million shares which calculate 4.45 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 27 to the stock, which implies a rise of 51.37% to its current value. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 30. It follows that stock’s current price would jump 54.3% in reaching the projected high whereas dropping to the targeted low would mean a gain of 54.3% for stock’s current value.
Centessa Pharmaceuticals plc ADR (CNTA) estimates and forecasts
And 7 analysts are in estimates of company making revenue of 714.29k in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -210.04% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 37.42% while estimates for its earnings growth in next 5 years are of 8.99%.
Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA)’s Major holders
Insiders are in possession of 0.50% of company’s total shares while institution are holding 96.60 percent of that, with stock having share float percentage of 97.09%. Investors also watch the number of corporate investors in a company very closely, which is 96.60% institutions for Centessa Pharmaceuticals plc ADR that are currently holding shares of the company. MEDICXI VENTURES MANAGEMENT (JERSEY) LTD is the top institutional holder at CNTA for having 19.96 million shares of worth $180.27 million. And as of 2024-06-30, it was holding 18.233 of the company’s outstanding shares.
The second largest institutional holder is GENERAL ATLANTIC, L.P., which was holding about 9.68 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.8427 of outstanding shares, having a total worth of $87.43 million.
On the other hand, T. Rowe Price Health Sciences Fund, Inc. and Fidelity Select Portfolios-Biotechnology Portfolio are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 3.31 shares of worth $43.48 million or 2.48% of the total outstanding shares. The later fund manager was in possession of 2.98 shares on Apr 30, 2025 , making its stake of worth around $39.08 million in the company or a holder of 2.23% of company’s stock.
